Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01915602
Title Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Bayer
Indications

hepatocellular carcinoma

Therapies

Refametinib + Sorafenib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT

Additional content available in CKB BOOST